Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01034696 | Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting | completed | — | 250 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT02285413 | Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients | completed | Phase 2 | 54 | Radboud University Medical CenterOTHER | 1 | May 4, 2016 |
| NCT00412581 | Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 29, 2016 | clinicaltrials |
| NCT02755233 | Ipilimumab-induced Lung Toxicity: Observational Study(Ipi-Lu-Tox) | completed | — | 71 | University of ZurichOTHER | 1 | Apr 28, 2016 | clinicaltrials |
| NCT01556503 | Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis | completed | — | 24 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 25, 2016 | clinicaltrials |
| NCT01425749 | Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI(Mel55) | completed | Early Phase 1 | 25 | Craig L Slingluff, JrOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00004104 | Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02088762 | Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm) | completed | — | 325 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01744860 | Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples | completed | — | 420 | Hoffmann-La RocheINDUSTRY | 1 | Mar 28, 2016 | clinicaltrials |
| NCT00026221 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01990859 | Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients | completed | Phase 2 | 20 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT02129049 | Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children | completed | N/A | 35 | University of WashingtonOTHER | 1 | Mar 9, 2016 | clinicaltrials |
| NCT01665183 | Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 2 | Feb 25, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01455259 | Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Uppsala UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00738361 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery | completed | Phase 2 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00588341 | Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection | completed | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT02662725 | Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases(IPI+RTS) | completed | Phase 2 | 73 | University Hospital, LilleOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01435369 | Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma | completed | Phase 2 | 103 | Medivation, Inc.INDUSTRY | 2 | Jan 21, 2016 | clinicaltrials |
| NCT01621295 | Assessing the Patient Experience in Cancer Care | completed | — | 408 | Mayo ClinicOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT01983124 | Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib(BeyPro1) | completed | Phase 2 | 31 | Paola QueiroloOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00462982 | Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
| NCT00574977 | Safety Study of Modified Vaccinia Virus to Cancer | completed | Phase 1 | 26 | David BartlettOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT02224768 | YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey | completed | — | 158 | Bristol-Myers SquibbINDUSTRY | 2 | Dec 21, 2015 | clinicaltrials |
| NCT00289016 | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | completed | Phase 2 | 50 | BioVex LimitedINDUSTRY | 2 | Dec 18, 2015 | clinicaltrials |
| NCT00574392 | Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo | completed | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2015 | clinicaltrials |
| NCT01368276 | An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma | completed | Phase 3 | 31 | BioVex LimitedINDUSTRY | 2 | Dec 18, 2015 | clinicaltrials |
| NCT02574260 | An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) | completed | Phase 2 | 3 | BioVex LimitedINDUSTRY | 0 | Dec 17, 2015 | clinicaltrials |
| NCT00006022 | Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer | completed | Phase 1 | 17 | Virginia Commonwealth UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT00185302 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma | completed | Phase 2 | 28 | BayerINDUSTRY | 0 | Dec 14, 2015 | clinicaltrials |
| NCT00257465 | Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma | completed | Phase 1 / Phase 2 | 82 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00625456 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | completed | Phase 1 | 23 | Jennerex BiotherapeuticsINDUSTRY | 2 | Dec 3, 2015 | clinicaltrials |
| NCT02417948 | Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans | completed | N/A | 143 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00833807 | Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver | completed | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT00096382 | Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00923195 | Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00110019 | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 3 | 823 | National Cancer Institute (NCI)NIH | 2 | Oct 19, 2015 | clinicaltrials |
| NCT00665470 | Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00749684 | Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083) | completed | — | 138 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 19, 2015 | clinicaltrials |
| NCT00276536 | Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma(IFNa) | completed | Phase 1 | 35 | The Cleveland ClinicOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT00612664 | Phase II, 2nd Line Melanoma - RAND Monotherapy | completed | Phase 2 | 158 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 12, 2015 | clinicaltrials |
| NCT01295931 | Nuclear and Near-Infrared (NIR) Imaging in Melanoma | completed | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01376713 | Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma | completed | Phase 2 | 10 | Medical University of ViennaOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00002973 | Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma | completed | Phase 2 | 34 | University of Wisconsin, MadisonOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00085306 | Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma | completed | Phase 2 | 21 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00317759 | Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 1, 2015 | clinicaltrials |
Data updated 24 days agoSource updated May 23, 2016source: clinicaltrials